Traders should consider the arbitrage spread between the current price and the $3.16 cash offer, accounting for deal risks. Key catalysts are the proxy filing and shareholder vote. Monitor regulatory approvals and any competing bids. The CVRs provide additional upside tied to net sales milestones.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 1 $3.11entry
- T+1 · 7mo ago +0.32%α +0.66% · $3.12
- T+5 · 6mo ago +0.96%α −1.38% · $3.14
- T+20 · 6mo ago +0.64%α −4.64% · $3.13
- T+60 · due 4mo ago Pending
Price Chart
How similar events traded
Executive Summary
Esperion has agreed to be acquired by ARCHIMED for $3.16 per share in cash at closing, plus contingent milestone payments of up to $100 million, representing a total equity value of up to approximately $1.1 billion. The upfront cash consideration offers a 58% premium to the closing price on April 30, 2026. The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals.
Key Financial Metrics
Key Facts
- Acquisition price of $3.16 per share in cash, plus CVRs for up to $100 million in aggregate milestone payments
- Total equity value up to approximately $1.1 billion on a fully diluted basis
- Premium of 58% to Esperion's closing stock price on April 30, 2026
- Board unanimously approved; recommends shareholders vote in favor
- Expected to close in Q3 2026
- Debt financing from Pharmakon Advisors; no financing condition
Financial Impact
Upfront cash of $3.16 per share (58% premium) plus contingent milestone payments up to $0.39 per share, for total potential value of ~$3.55 per share
Risk Factors
- Shareholder approval required; potential opposition
- Regulatory approvals needed (HSR, etc.)
- Deal termination risk; if conditions not met, stock may drop back to pre-announcement levels
- CVR payments are contingent on commercial performance and may not materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285833 |
Track record
21 reports on ESPR
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers